Akt
PKB; Protein kinase B
Akt/PKB (Protein kinase B), a serine/threonine protein kinase with antiapoptotic activity, is one of the major downstream targets of PtdIns(3,4,5)P3 signaling pathway. It contains a pleckstrin homology domain (PH domain) that specifically binds PtdIns(3,4,5)P3 on the plasma membrane. Akt phosphorylation and activation are directly determined by the level of PtdIns(3,4,5)P3 on the plasma membrane, which is regulated by PI3K.
Akt consists of three isoforms: PKBα/Akt1, PKBβ/Akt2 and PKBγ/Akt3. Akt isoforms have an N-terminal PH (pleckstrin homology) domain and a kinase domain, which are separated by a 39-amino-acid hinge region. Catalytically active Akt regulates the function of numerous substrates involved in cell survival, growth, proliferation, metabolism and protein synthesis.
Akt is a crucial mediator of cell survival and its deactivation is implicated in various stress-induced pathological cell death and degenerative diseases.
Akt Isoform Specific Products
All Product Categories
-
Akt Inhibitors
(1020)
View all products
-
Akt Agonists
(7)
View all products
-
Akt Activators
(301)
View all products
-
Akt Modulators
(25)
View all products
-
Akt Chemical
(1)
View all products
-
Akt Inducers
(9)
View all products
-
Akt Degraders
(11)
View all products
-
Akt Control
(1)
View all products
-
Akt Substrate
(1)
View all products
-
Akt Ligands
(6)
View all products
-
AKT Serine/Threonine Kinase 2 (AKT2) Proteins
(5)
View all products
-
AKT Serine/Threonine Kinase 3 (AKT3) Proteins
(6)
View all products
-
Akt Related Products (1489)
Related Products (1489)
-
Recombinant Proteins (11)
-
Antibodies (11)
-
Akt Isoform Comparison
-
cis,trans-Germacrone
0 ImagesCat. No.: HY-145670CAS No.: 32663-51-7cis,trans-Germacrone is an isomer of Germacrone (HY-N0440) and is present in the stems and leaves of Curcuma wenyujin. Germacrone exhibits a wide range of antitumor, antioxidant, and anti-inflammatory effects. Germacrone inhibits lung cancer cell proliferation and alters Akt/MDM2/p53. Germacrone also induces cell cycle arrest at the G1/S phase. Germacrone is used in lung cancer-related research.
-
SS-3091
0 ImagesCat. No.: HY-178042CAS No.: 2756257-56-2SS-3091 is a pan-KRas inhibitor active across KRasG12D, KRasG12C, KRasG12V, KRasG12S mutants, with minimal effects on non-KRas-driven cancer cells. SS-3091 binds to the KRas·ARaf interaction interface, destabilizes the complex, and attenuates KRas activity. SS-3091 suppresses phosphorylation of S6K, Akt, and ERK. SS-3091 reduces proliferation and decreases colony formation of cancer cells bearing KRasG12 mutations. SS-3091 can be used for the research of KRas-driven cancers.
-
Archexin sodium scrambled negative control
0 ImagesCat. No.: HY-177616BArchexin sodium scrambled negative control is the sequence scrambled negative control of Archexin sodium.
-
AKT ligand-2
0 ImagesCat. No.: HY-48682CAS No.: 2376139-61-4AKT ligand-2 (compound 5) is an AKT ligand. AKT ligand-2 can be combined with VHL ligand (S,R,S)-AHPC (HY-125845) through linker to synthesize PROTAC MS21 (HY-141807).
-
GTx-134
0 ImagesCat. No.: HY-13312ACAS No.: 1008448-19-8GTx-134 is a dual insulin-like growth factor 1 receptor/insulin receptor (IGF-1R/IR) inhibitor with an IC50 values for IGF-1R and IR of 97 and 187 nM respectively. GTx-134 inhibits the autophosphorylation of IGF-1R and its downstream signaling pathway (Akt), thereby blocking the proliferation and survival signals of tumor cells. GTx-134 has broad-spectrum inhibitory activity against multiple myeloma cell lines and can induce apoptosis in sensitive cells. GTx-134 significantly inhibits tumor growth in mice with MM1.S cell transplantation. GTx-134 works in synergy with existing therapies (such as protease preparations, immunomodulators). GTx-134 can be used in high-risk myeloma research.
-
NSC 850745
0 ImagesCat. No.: HY-175848NSC 850745 is a selective and potent c-Met/STAT3 inhibitor with IC50 values of 210 and 670 nM. NSC 850745 can inhibit cell proliferation, induce G2/M phase arrest and induce apoptosis. NSC 850745 can downregulate AKT-1, VEGF and Bcl-2 expression and upregulate p53, Bax and caspase expression. NSC 850745 can be used for the research of cancer, such as leukemia and colon cancer.
-
M802
0 ImagesCat. No.: HY-P992401M802 is an anti-HER2/CD3 bispecific antibody, with a Kd of 0.578 nM for human HER2 and a Kd of 71.2 nM for human CD3. M802 inhibits the PI3K/AKT and MAPK signaling pathways, suppresses tumor cell proliferation, activates caspase-3, and promotes tumor cell apoptosis (apoptosis). M802 recruits and activates CD3-positive immune cells, mediates cytotoxicity against HER2-positive tumor cells, and induces immune cells to secrete IFN-γ, TNF-α, IL-2 and IL-6. M802 exhibits anti-tumor efficacy in mice with gastric cancer xenografts. M802 can be used in research related to HER2-positive breast cancer, HER2-positive gastric cancer and other cancers. The recommended isotype control is human IgG1 kappa (HY-P99001).
-
Desethylamiodarone hydrochloride (Standard)
0 ImagesCat. No.: HY-130353RCAS No.: 96027-74-6Synonyms: N-Desethylamiodarone hydrochloride (Standard); LB 33020 hydrochloride (Standard)Desethylamiodarone hydrochloride (Standard) (N-Desethylamiodarone hydrochloride (Standard); LB 33020 hydrochloride (Standard)) is the analytical standard of Desethylamiodarone hydrochloride (HY-130353). This product is intended for research and analytical applications. Desethylamiodarone hydrochloride (N-Desethylamiodarone hydrochloride; LB 33020 hydrochloride) is the major active metabolite of Amiodarone (HY-14187) generated via CYP3A4 metabolism. Desethylamiodarone hydrochloride downregulates p‑Akt, p‑Bad and Bcl‑2, upregulates Bax, promotes mitochondrial release of cytochrome c, activates caspase‑3 and cleaves PARP‑1, thereby inducing cell cycle arrest and apoptosis. Desethylamiodarone hydrochloride can be used in cervical cancer-related research.
-
Dehydroxy-oridonin-vinyl ester
0 ImagesCat. No.: HY-180192CAS No.: 3106089-54-4Dehydroxy-oridonin-vinyl ester (Compound 6k) is an anti-cancer agent. Dehydroxy-oridonin-vinyl ester exhibits extremely strong anti-proliferative activity against SU-DHL-6 cells, with its IC₅₀ value being 0.12 μM. Dehydroxy-oridonin-vinyl ester induces cell apoptosis by inhibiting the activation of the PI3K/Akt signaling pathway, without affecting the cell cycle progression. Dehydroxy-oridonin-vinyl can be used for the study of lymphoma.
-
ST-168
0 ImagesCat. No.: HY-120281CAS No.: 2126038-25-1ST-168 is an orally active MEK/PI3K inhibitor with an IC50 of 182 nM against MEK1 and IC50 values of 69.2, 41.7, 1482 and 2293 nM against PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ respectively. ST-168 completely inhibits the phosphorylation of ERK1/2 and AKT and induces cancer cell death in a 3D tumor sphere model. ST-168 demonstrates significant antitumor effects in the A375 melanoma mouse model. ST-168 improves the ocular toxicity profile of MEK inhibitors, showing lower caspase activation levels, indicating reduced apoptosis induction. ST-168 can be used in melanoma research.
-
Akt1-IN-4
0 ImagesCat. No.: HY-161439CAS No.: 3033577-05-5Akt1-IN-4 (Compound 62) is an AKT1-E17K inhibitor with an IC50 value of less than 15 nM.
-
KRAS-IN-58
0 ImagesCat. No.: HY-182749KRAS-IN-58 is a KRAS inhibitor with a IC50 of 0.223 μM against KRASG12D. KRAS-IN-58 binds to KRASG12C and KRASG12D proteins, and reduces the levels of phosphorylated Raf1, AKT and ERK in pancreatic cancer cells. KRAS-IN-58 can be used for the research of pancreatic cancer.
-
Puquitinib
0 ImagesCat. No.: HY-111137CAS No.: 916890-10-3Synonyms: XC-302 free basePuquitinib (XC-302 free base) is a multi-target inhibitor with the activity of inducing autophagy in nasopharyngeal carcinoma cells by inhibiting the PI3K/AKT/mTOR signaling pathway. Puquitinib was able to inhibit the proliferation of CNE-2 cells, showing a dose-dependent antiproliferative effect. Puquitinib induced the formation of autophagosomes and autolysosomes in CNE-2 cells, which were observed by fluorescence microscopy and electron microscopy. Puquitinib promoted the formation of LC3-II and increased the expression of beclin 1, while reducing the level of p62. Puquitinib inhibited the PI3K/AKT/mTOR pathway by reducing the expression of p-AKT and p-mTOR. Puquitinib also induced apoptosis in CNE-2 cells, and when autophagy was inhibited, the apoptosis rate was reduced, which means that autophagy may interact with apoptosis to induce cell death.
-
10-Gingerol (Standard)
0 ImagesCat. No.: HY-N0448RCAS No.: 23513-15-710-Gingerol (Standard) is the analytical standard of 10-Gingerol (HY-N0448). This product is intended for research and analytical applications. 10-Gingerol is an AMPK agonist, which is found in the ginger oleoresin from fresh rhizome with anti-inflammatory, antioxidant and anti-proliferative activities. 10-Gingerol suppresses neointimal hyperplasia and inhibits vascular smooth muscle cell proliferation. 10-Gingerol exhibits substantial scavenging activities with an IC50 value of 10.47 μM against DPPH radical, an IC50 value of 1.68 μM against superoxide radical and an IC50 value of 1.35 μM against hydroxyl radical. 10-Gingerol inhibits the proliferation of MDA-MB-231 tumor cell line with an IC50 of 12.1 μM. 10-Gingerol suppresses the proliferation, migration, invasion, and induced apoptosis through targeting the PI3K/Akt signaling pathway in MDA-MB-231/IR cells. 10-Gingerol is promising for research of ulcerative colitis.
-
ROR1-IN-3
0 ImagesCat. No.: HY-174382ROR1-IN-3 (Compound 24d) is a potent and highly selective ROR1 kinase inhibitor (IC50 = 17.6 nM). ROR1-IN-3 demonstrates robust antitumor activity and inhibitory effect against ROR1 both in vitro and in vivo. ROR1-IN-3 has robust antiproliferative efficacy in vitro and in vivo. ROR1-IN-3 induces apoptosis in cancer cell lines. ROR1-IN-3 inhibits ROR1 downstream AKT/mTOR and NF-κB signaling pathway. ROR1-IN-3 can be studied in antitumor research.
-
Bisdemethoxycurcumin
0 ImagesCat. No.: HY-N2942CAS No.: 52328-96-8Bisdemethoxycurcumin is an orally effective curcuminoid. Bisdemethoxycurcumin downregulates pro-inflammatory cytokines in macrophages by inhibiting the phosphorylation of PI3K/Akt and p38 MAPK. Bisdemethoxycurcumin relieves autophagy inhibition and promotes lipophagy to clear vascular smooth muscle foam cells by inhibiting the PDK1/Akt/mTOR pathway. Bisdemethoxycurcumin activates the cAMP/Epac/AMPKα axis and the NRF2/HO-1 antioxidant axis, thereby indirectly inhibiting the phosphorylation of NF-κB p65 and pro-inflammatory outputs such as IL-1β/IL-6/TNF-α, so as to alleviate pulmonary oxidative stress, inflammatory infiltration and pulmonary edema. Bisdemethoxycurcumin blocks NLRP3-mediated pyroptosis and protects cartilage extracellular matrix degradation by activating NRF2/HO-1. Bisdemethoxycurcumin also exerts a synergistic effect with potassium iodide against Candida.
-
PI3Kδ-IN-24
0 ImagesCat. No.: HY-175002CAS No.: 3051829-20-7PI3Kδ-IN-24 is a selective PI3Kδ inhibitor (IC50 = 0.1 nM). PI3Kδ-IN-24 exhibits significant antiproliferative effects against PI3Kδ-overexpressing cancer cell lines. PI3Kδ-IN-24 reduces p-AKT levels and induces cell cycle arrest and apoptosis in tumor cells. PI3Kδ-IN-24 is useful in cancer research, such as diffuse large B-cell lymphoma (DLBCL).
-
(+)-Neoalbaconol
0 ImagesCat. No.: HY-N20662CAS No.: 2779545-15-0(+)-Neoalbaconol is a selective Akt/PDK1 inhibitor (with an IC50 of 10 μM against hPDK1). (+)-Neoalbaconol selectively inhibits cancer cell proliferation, and induces energy depletion, apoptosis, autophagy and necroptosis in cancer cells. In addition, (+)-Neoalbaconol downregulates cIAP1/2 and TRAFs to activate non-canonical NF-κB and promote TNFα transcription, blocks EGFR-mediated VEGF production and receptor activation, and mediates cell necrosis via the RIPK3-ROS-dependent pathway. (+)-Neoalbaconol can be used in research related to nasopharyngeal carcinoma, melanoma, breast cancer and gastric cancer.
